Heron Therapeutics (HRTX) PT Raised to $46 at Leerink Partners; 'Focus Moving to HTX-011's Commercialization'
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Price: $0.40 -2.44%
Rating Summary:
18 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Rating Summary:
18 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Join SI Premium – FREE
Leerink Partners raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $46.00 (from $36.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR18 at JPMorgan
- Oxford Industries (OXM) PT Lowered to $40 at UBS Amid Top-line Weakness
- Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$231 at Bernstein SocGen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
